Respiratory Pathogen Panels

GenMark’s Respiratory Pathogen Panels detects and identify the most common viral and bacterial organisms associated with upper respiratory infection.

Available on the ePlex System


2019 Novel Coronavirus (Wuhan Virus) Technical Bulletin

Clinical Impact of Respiratory Tract Infections – More Than Just Flu

Respiratory infections cause more doctor visits and absences from school and work than any other illness.[1] It is estimated that ~10% of people in the U.S. and Europe are infected with influenza each year during flu season; globally resulting in about 3-5 million severe cases and 250,000-500,000 deaths every year.[2][3][4] However, it is not just influenza that can cause respiratory infections; in addition to the flu, there are approximately 500 million non–influenza respiratory infections occurring annually.[5]

Comprehensive Diagnosis Impacts Patient Care

The clinical presentation of respiratory pathogens is very similar, thus complicating proper diagnosis and appropriate therapy selection. The comprehensive design of the ePlex RP Panel may help improve patient care by identifying pathogens that are often missed by traditional methods. Accurately determining the cause of infection has been shown to reduce length of stay and time in isolation.[6] Accurate diagnosis also improves patient cohorting and decreases the risk of hospital acquired infection.[7]


  • Adenovirus
  • Coronavirus 229E
  • Coronavirus HKU1
  • Coronavirus NL63
  • Coronavirus OC43
  • SARS-CoV-2
  • Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
  • Human Bocavirus
  • Human Metapneumovirus
  • Human Rhinovirus/Enterovirus
  • Influenza A
  • Influenza A H1
  • Influenza A H1-2009
  • Influenza A H3
  • Influenza B
  • Parainfluenza 1
  • Parainfluenza 2
  • Parainfluenza 3
  • Parainfluenza 4
  • Respiratory Syncytial Virus A
  • Respiratory Syncytial Virus B


  • Bordetella pertussis
  • Chlamydia pneumoniae
  • Legionella pneumophila
  • Mycoplasma pneumoniae

Rapid, Actionable Results Can Improve Outcomes and Reduce Cost of Care

While many systems claim sample-to-answer capabilities, only ePlex is able to integrate the entire process from order-to-report to better realize the benefits of rapid, multiplex molecular diagnostics.  ePlex is the True Sample-to-Answer Solution™ because it improves overall turnaround time with end-to-end integration that includes:

  • Bi-directional LIS to automate and accelerate order entry and results reporting
  • Random and continuous access and a modular, scalable design to ensure capacity that meets peak season demand
  • Independently validated shortest hands-on time in the lab

Multiple studies have shown that rapid multiplex molecular diagnostics for respiratory pathogens can help improve outcomes, reduce cost-of-care and support key quality initiatives.[6][7] The ePlex system and the comprehensive ePlex RP panel provide physicians the actionable information they need to make timely treatment decisions.

Order-to-Report Is what Matters Most

The green time stamps are commonly documented in typical hospital and laboratory information systems. ePlex is designed to improve true turnaround time from order-to-report with a LEAN workflow by eliminating manual steps and staging of samples that often delay and complicate efficient test processing and result reporting. 

To learn more about the Respiratory Pathogen Panels or to schedule a demonstration, contact us at + 60 or email us.

CE-IVD. Not available for sale in the US.

[1] Johns Hopkins Medicine Health Library.,P02966 (accessed February 2016)
[3] European Centre for Disease Prevention and Control. Seasonal Influenza. (accessed February 2016)
[4] World Health Organization. (2014). Seasonal Influenza Fact Sheet 211.
[5] Fendrick A, et al. (2003) The Economic Burden of Non-Influenza-Related Viral Respiratory Tract Infection in the United States. Arch Intern Med 163(4):487-94.
[6] Rogers, B. et al. 2015. Impact of a Rapid Respiratory Panel Test on Patient Outcomes. Archives of Pathology and Laboratory Medicine. 139:636‐641.
[7] R.M. Martinez, H.E.Ka, L.M. Scicchitano, and D.M. Wolk, Geisinger Health System, Department of Laboratory Medicine, Danville PA, Wilkes Univ., Wilkes-Barre, PA

popup close button